Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction

Chang, Meng-Wei; Yu, Yi; Chang, Chih Han; Tang, Alan C.L.; Liao, Wei Yin; Cheng, Fan‐Tien; Yeh, Chen Sheng; Lai, James J.; Stayton, Patrick S.; Hsieh, Patrick C.

doi:10.1016/j.jconrel.2013.04.022

Cited by 122 publications

(76 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the current therapies are mainly palliative. 31 Thus, new therapies must be developed to overcome the poor prognosis of MI. Several alternative strategies based on drug treatments, 32 injections of stem cells or proteins, 4,5 surgical interventions 33 and epicardial restraint devices 34 have been used to regenerate the infarcted heart.…”

Section: Discussionmentioning

confidence: 99%

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Qi¹,

Lü

Li³

et al. 2017

IJN

View full text Add to dashboard Cite

The local, intramyocardial injection of proteins into the infarcted heart is an attractive option to initiate cardiac regeneration after myocardial infarction (MI). Liraglutide, which was developed as a treatment for type 2 diabetes, has been implicated as one of the most promising protein candidates in cardiac regeneration. A significant challenge to the therapeutic use of this protein is its short half-life in vivo. In this study, we evaluated the therapeutic effects and long-term retention of liraglutide loaded in poly(lactic- co -glycolic acid)–poly(ethylene glycol) (PLGA–PEG) nanoparticles (NP-liraglutide) on experimental MI. PLGA–PEG nanoparticles (NPs) have been shown to efficiently load liraglutide and release bioactive liraglutide in a sustained manner. For in vitro test, the released liraglutide retained bioactivity, as measured by its ability to activate liraglutide signaling pathways. Next, we compared the effects of an intramyocardial injection of saline, empty NPs, free liraglutide and NP-liraglutide in a rat model of MI. NPs were detected in the myocardium for up to 4 weeks. More importantly, an intramyocardial injection of NP-liraglutide was sufficient to improve cardiac function ( P <0.05), attenuate the infarct size ( P <0.05), preserve wall thickness ( P <0.05), promote angiogenesis ( P <0.05) and prevent cardiomyocyte apoptosis ( P <0.05) at 4 weeks after injection without affecting glucose levels. The local, controlled, intramyocardial delivery of NP-liraglutide represents an effective and promising strategy for the treatment of MI.

show abstract

Section: Discussionmentioning

confidence: 99%

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Qi¹,

Lü

Li³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…With a decrease in the size of the PLGA, the amount of IGF-1 complexed in it increases considerably and, hence, enhanced Akt phosphorylation activity. 74 It is suggested that the pretreatment of hMSCs with scaffolds having high oxygen-carrying capacity may result in the preferential cardiomyogenic differentiation, ex vivo. The high oxygen-carrying capacity of electrospun hemoglobin/ gelatin/fibrinogen nanofibers has been used to treat MSCs, which has led to their enhanced differentiation into cardiomyocytes.…”

Section: Myocardial Regenerationmentioning

confidence: 99%

Regenerative nanomedicine: current perspectives and future directions

Chaudhury¹,

Kumar²,

Kandasamy³

et al. 2014

IJN

View full text Add to dashboard Cite

Nanotechnology has considerably accelerated the growth of regenerative medicine in recent years. Application of nanotechnology in regenerative medicine has revolutionized the designing of grafts and scaffolds which has resulted in new grafts/scaffold systems having significantly enhanced cellular and tissue regenerative properties. Since the cell–cell and cell-matrix interaction in biological systems takes place at the nanoscale level, the application of nanotechnology gives an edge in modifying the cellular function and/or matrix function in a more desired way to mimic the native tissue/organ. In this review, we focus on the nanotechnology-based recent advances and trends in regenerative medicine and discussed under individual organ systems including bone, cartilage, nerve, skin, teeth, myocardium, liver and eye. Recent studies that are related to the design of various types of nanostructured scaffolds and incorporation of nanomaterials into the matrices are reported. We have also documented reports where these materials and matrices have been compared for their better biocompatibility and efficacy in supporting the damaged tissue. In addition to the recent developments, future directions and possible challenges in translating the findings from bench to bedside are outlined.

show abstract

“…IGF-NPs treated animals also showed a significant reduction in infarct size and number of apoptotic CMCs and improved LV-EF 21 days after treatment compared to free IGF administration and non loaded NPs. Finally, the authors reported that 60 nm NPs were most effective in binding IGF-1 and consequently preventing CMCs apoptosis [122]. Our group has also examined the feasibility of using PLGA-MPs encapsulating therapeutic proteins to promote cardiac regeneration.…”

Section: Nano/microparticles In Protein-based Therapiesmentioning

confidence: 99%

Heart regeneration after myocardial infarction using synthetic biomaterials

Pascual-Gil

Garbayo

Díaz-Herráez

et al. 2015

Journal of Controlled Release

122

View full text Add to dashboard Cite

Abstract:Myocardial infarction causes almost 7.3 million deaths each year worldwide. However, current treatments are more palliative than curative. Presently, cell and protein therapies are considered the most promising alternative treatments. Clinical trials performed until now have demonstrated that these therapies are limited by protein short half-life and by low transplanted cell survival rate, prompting the development of novel cell and protein delivery systems able to overcome such limitations. In this review we discuss the advances made in the last 10 years in the emerging field of cardiac repair using biomaterial-based delivery systems with focus on the progress made on preclinical in vivo studies. Then, we focus in cardiac tissue engineering approaches, and how the incorporation of both cells and proteins together into biomaterials has opened new horizons in the myocardial infarction treatment. Finally, the ongoing challenges and the perspectives for future work in cardiac tissue engineering will also be discussed.

show abstract

Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction

Cited by 122 publications

References 45 publications

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

Regenerative nanomedicine: current perspectives and future directions

Heart regeneration after myocardial infarction using synthetic biomaterials

Contact Info

Product

Resources

About